Lv1
20 积分 2022-09-30 加入
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
1天前
待确认
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
1天前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
5天前
已完结
Microwave ablation versus laparoscopic resection as first‐line therapy for solitary 3–5‐cm HCC
13天前
已完结
Macrophages harness hepatocyte glutamate to boost liver regeneration
14天前
已完结
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
1个月前
已完结
Postoperative hepatic insufficiency despite preoperative portal vein embolization: Not just about the volumetrics
1个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
2个月前
已完结
Remain recipient partial liver during liver transplant after Hassab
3个月前
已完结
皖公网安备34019202002308
